| 前收盘价格 | 19.00 |
| 收盘价格 | 19.19 |
| 成交量 | 1,169,546 |
| 平均成交量 (3个月) | 757,052 |
| 市值 | 1,317,230,208 |
| 价格/销量 (P/S) | 6.50 |
| 股市价格/股市净资产 (P/B) | 2.25 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -191.56% |
| 营业利益率 (TTM) | -58.89% |
| 稀释每股收益 (EPS TTM) | -4.79 |
| 季度收入增长率 (YOY) | 196.00% |
| 总债务/股东权益 (D/E MRQ) | 0.26% |
| 流动比率 (MRQ) | 4.17 |
| 营业现金流 (OCF TTM) | -258.30 M |
| 杠杆自由现金流 (LFCF TTM) | -170.11 M |
| 资产报酬率 (ROA TTM) | -20.07% |
| 股东权益报酬率 (ROE TTM) | -59.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Arvinas, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.00 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 7.21% |
| 机构持股比例 | 108.73% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 30 Sep 2024 | 1,434,721 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 88.00 (BMO Capital, 359.05%) | 购买 |
| 中 | 71.00 (270.37%) | |
| 低 | 40.00 (Oppenheimer, 108.66%) | 购买 |
| 平均值 | 67.50 (252.11%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 23.71 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 87.00 (353.83%) | 购买 | 22.54 |
| 31 Oct 2024 | 87.00 (353.83%) | 购买 | 26.43 | |
| BMO Capital | 20 Nov 2024 | 88.00 (359.05%) | 购买 | 22.69 |
| Stephens & Co. | 18 Nov 2024 | 55.00 (186.91%) | 购买 | 23.19 |
| Oppenheimer | 31 Oct 2024 | 40.00 (108.66%) | 购买 | 26.43 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合